Abstract:A PEG‐sheddable and M2 tumor‐associated macrophages (TAMs) targeted nanodrug is developed to augment intratumoral effector T cells for enhanced immunotherapy of breast cancer. The nanodrug incorporating STAT6 inhibitor (AS) and anti‐Galectin‐9 antibody (aG‐9) repolarizes M2‐TAMs into tumoricidal M1 phenotype and promotes the infiltration of effector T cells to thus synergize with aG‐9 blockade to boost the cancer immunotherapy. Low infiltration of cytotoxic T lymphocytes and their exhaustion manifest the two concurrent main hurdles for achieving effective tumor immunotherapy of triple‐negative breast cancer. It is found that Galectin‐9 blockage can revise the exhaustion of effector T cells, meanwhile the repolarization of protumoral M2 tumor‐associated macrophages (TAMs) into tumoricidal M1‐like ones can recruit effector T cells infiltrating into tumor to boost immune responses. Herein, a sheddable PEG‐decorated and M2‐TAMs targeted nanodrug incorporating Signal Transducer and Activator of Transcription 6 inhibitor (AS) and anti‐Galectin‐9 antibody (aG‐9) is prepared. The nanodrug responds to acidic tumor microenvironment (TME) with the shedding of PEG corona and the release of aG‐9, exerting local blockade of PD‐1/Galectin‐9/TIM‐3 interaction to augment effector T cells via exhaustion reversing. Synchronously, targeted repolarization of M2‐TAMs into M1 phenotype by AS‐loaded nanodrug is achieved, which promotes tumor infiltration of effector T cells and thus synergizes with aG‐9 blockade to boost the therapeutic efficacy. Besides, the PEG‐sheddable approach endows nanodrug with stealth ability to reduce immune‐related adverse effects caused by AS and aG‐9. This PEG sheddable nanodrug holds the potential to reverse the immunosuppressive TME and increase effector T cell infiltration, which dramatically enhances immunotherapy in highly malignant breast cancer.

Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells

Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo‐immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment

Entrapping multifunctional dendritic nanoparticles into a hydrogel for local therapeutic delivery and synergetic immunochemotherapy

Mature Dendritic Cell-Derived Dendrosomes Swallow Oxaliplatin-Loaded Nanoparticles to Boost Immunogenic Chemotherapy and Tumor Antigen-Specific Immunotherapy

Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy

Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy

Chemotherapy Mediated by Biomimetic Polymeric Nanoparticles Potentiates Enhanced Tumor Immunotherapy Via Amplification of Endoplasmic Reticulum Stress and Mitochondrial Dysfunction

Core-shell Tecto Dendrimer-Mediated Cooperative Chemoimmunotherapy of Breast Cancer

Transcytosis Mediated Deep Tumor Penetration for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Immuno-modulation of tumor and tumor draining lymph nodes through enhanced immunogenic chemotherapy by nano-complexed hyaluronic acid/polyvinyl alcohol microneedle

A Tumor‐Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer

Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer

Protein-assisted Synthesis of Chitosan-Coated Minicells Enhance Dendritic Cell Recruitment for Therapeutic Immunomodulation Within Pulmonary Tumors

PEG‐Sheddable Nanodrug Remodels Tumor Microenvironment to Promote Effector T Cell Infiltration and Revise Their Exhaustion for Breast Cancer Immunotherapy

Slimming and Reinvigorating Tumor-Associated Dendritic Cells with Hierarchical Lipid Rewiring Nanoparticles

Enhancing Therapeutic Effects of Docetaxel-Loaded Dendritic Copolymer Nanoparticles by Co-Treatment with Autophagy Inhibitor on Breast Cancer

Dynamic regulation of drug biodistribution by turning tumors into decoys for biomimetic nanoplatform to enhance the chemotherapeutic efficacy of breast cancer with bone metastasis

A Dendritic Cell-Like Biomimetic Nanoparticle Enhances T Cell Activation for Breast Cancer Immunotherapy

Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics

Combination Therapy with Epigenetic-Targeted and Chemotherapeutic Drugs Delivered by Nanoparticles to Enhance the Chemotherapy Response and Overcome Resistance by Breast Cancer Stem Cells.